Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
about
Stem Cell Modeling of Core Binding Factor Acute Myeloid LeukemiaAcute Myeloid Leukemia: A Concise ReviewMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesRisk factors for relapse after allogeneic transplantation in acute myeloid leukemiaMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceAn update of current treatments for adult acute myeloid leukemiaNovel therapeutic options in Acute Myeloid LeukemiaMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsNovel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisPrognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemiaSmall-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaAcute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signalingDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Highlights from the 58th meeting of the American Society of Haematology, 1-6 December 2016, San Diego, USA.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Leukemia diagnosis: today and tomorrow.Circulating DNA in solid organ cancers-analysis and clinical application.Acute myeloid leukemia--major progress over four decades and glimpses into the future.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Frontline treatment of acute myeloid leukemia in adults.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsLife after transplant: are we becoming high maintenance in AML?Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.Acute Myeloid Leukemia: How Do We Measure Success?Biological and clinical consequences of NPM1 mutations in AML.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Minimal residual disease in acute myelogenous leukemia.
P2860
Q26765858-96805523-648C-4A5E-A59E-A559C52ABEE2Q26766719-EA8A8BB6-1BA6-4C0E-B62D-3F8CE7D32DE9Q26770394-A667B3C7-2959-4112-BB2B-4762ECA04DC5Q26771438-28FBF740-F3A2-4C6A-A7D5-7D7BAE9029B4Q26776393-FB62C59E-27C9-4504-989F-2486C2C4F7B5Q26776396-08C94DC0-3F0E-4D1A-B610-26CAC87C81CEQ28069889-F7E3256E-F076-4F96-88AB-46810AE47BF4Q28073464-D9850911-2E96-4C2B-8BDE-75802F4DC9C8Q28075654-73D4FD7C-2AF1-4B18-B799-129680AAD40FQ28087291-0BB1294F-4D7C-498B-B1FB-9449402BE71EQ30234914-181BE72F-8FB8-4F71-B007-2CD85765C0AAQ33815986-22D05C99-F09F-45C1-807B-4B22BEBEAB91Q35348105-878C7108-A0EF-49D7-88CD-25B13C6FAE29Q35546759-2211460E-3440-4F3A-9CD8-B9F1CC53363CQ35604619-3362D2F2-CE7E-483E-9859-46FCC798F9B6Q36020938-820D6B62-8586-4B4A-AC9D-2787B8759E38Q36430867-312E1040-0A63-4B04-B48E-0D971CF1F2F1Q37072126-63814943-0309-46D2-8281-3EAAC56A16EDQ37141503-B8E3B9E9-05A0-4E06-8DD8-8638A361325CQ37216267-79C5186E-F8D4-4B00-9042-653CA1AB0E8CQ37270982-C3546F6E-6A31-4860-A27B-2019D7F11023Q37607838-72C71E0E-582B-420C-BAB4-7533178D99F6Q37624593-7353BC94-02C4-48D5-A6FC-B0C5C36B76BEQ37672472-BC7DDFF5-50E2-4EDF-8A77-3556A568CE9CQ37720728-D77CEB0F-D9BF-4740-8E38-F6CD7AB40CA9Q38494659-18F177CC-DCD2-4995-9347-4923768070D5Q38537725-3372F91F-6B1A-4CD0-816E-B465E77486C3Q38580327-1CB859F3-846A-4B81-9CC9-5500F83F06B7Q38644941-9A766892-69CC-4F17-B8FD-8F095274E994Q38672646-C33ED2C1-B9EB-4F0C-B4E3-BFA43BDC29CEQ38676574-AD396B5C-54CF-463D-A97D-9FE8D64D4F68Q38703904-3BE2D966-A046-4335-844C-5A8FCC61B5E2Q38767583-A54D5073-F708-4D32-BACB-21C608DEEB75Q38789282-6407444C-77DA-42B7-BC02-8D953EA5E095Q38801124-ADA44DDC-546D-4432-9363-EAF655B68C1BQ38881996-3D15A623-866A-4261-AC76-DB63206DFD92Q38948650-52B800E7-4B59-4C97-B8A0-F7A014AD0115Q39098284-B46A8969-DD1D-4D30-A24A-557B6255325CQ39132424-047D6B73-6E17-45A5-B2AD-199930F24930Q39266354-1487135B-7CAD-49BE-BBB9-A22EA05C6A87
P2860
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Defining minimal residual dise ...... ms are ready for "prime time"?
@ast
Defining minimal residual dise ...... ms are ready for "prime time"?
@en
Defining minimal residual dise ...... ms are ready for "prime time"?
@nl
type
label
Defining minimal residual dise ...... ms are ready for "prime time"?
@ast
Defining minimal residual dise ...... ms are ready for "prime time"?
@en
Defining minimal residual dise ...... ms are ready for "prime time"?
@nl
prefLabel
Defining minimal residual dise ...... ms are ready for "prime time"?
@ast
Defining minimal residual dise ...... ms are ready for "prime time"?
@en
Defining minimal residual dise ...... ms are ready for "prime time"?
@nl
P3181
P1433
P1476
Defining minimal residual dise ...... ms are ready for "prime time"?
@en
P2093
David Grimwade
P304
P3181
P356
10.1182/BLOOD-2014-05-577593
P407
P577
2014-11-27T00:00:00Z